Axl receptor tyrosine kinase is a novel target of apigenin for the inhibition of cell proliferation

International Journal of Molecular Medicine

Volumn 34, Issue 2, 2014, Pages 592-598

  Kim, Kyung Chan ^a   Choi, Eun Ha ^b   Lee, Chuhee ^b  

^a Catholic University of Daegu   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Apigenin; Axl; Lung cancer; p21; X linked inhibitor of apoptosis

Indexed keywords

APIGENIN; AXL RECEPTOR TYROSINE KINASE; PROTEIN P21; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ONCOPROTEIN; P21 ACTIVATED KINASE; XIAP PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL LYSATE; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

APIGENIN; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P21-ACTIVATED KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84904268487     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1804     Document Type: Article

References (45)

1. Liu C, Tu FX and Chen X: Neuroprotective effects of apigenin on acute transient focal cerebral ischemia-reperfusion injury in rats. Zhong Yao Cai 31: 870-873, 2008 (In Chinese).
2. Svehliková V, Bennett RN, Mellon FA, et al: Isolation, identification and stability of acylated derivatives of apigenin 7-O-glucoside from chamomile (Chamomilla recutita [L.] Rauschert). Phytochemistry 65: 2323-2332, 2004. (Pubitemid 39237248)
3. Birt DF, Hendrich S and Wang W: Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90: 157-177, 2001. (Pubitemid 32913477)
4. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
5. Manach C, Scalbert A, Morand C, Rémésy C and Jiménez L: Polyphenols: food sources and bioavailability. Am J Clin Nutr 79: 727-747, 2004. (Pubitemid 41103873)
6. Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21: 381-406, 2001. (Pubitemid 32695277)
7. Bevilacqua L, Buiarelli F, Coccioli F and Jasionowska R: Identification of compounds in wine by HPLC-tandem mass spectrometry. Ann Chim 94: 679-689, 2004. (Pubitemid 39297619)
8. Zheng PW, Chiang LC and Lin CC: Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci 76: 1367-1379, 2005.
9. Lu HF, Chie YJ, Yang MS, et al: Apigenin induces apoptosis in human lung cancer H460 cells through caspase- and mitochondria-dependent pathways. Hum Exp Toxicol 30: 1053-1061, 2011.
10. Zhong Y, Krisanapun C, Lee SH, et al: Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer 46: 3365-3374, 2010.
11. Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H and Peppelenbosch MP: Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis 1: e19, 2010.
12. Li ZD, Hu XW, Wang YT and Fang J: Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1. FEBS Lett 583: 1999-2003, 2009.
13. Shukla S, MacLennan GT, Flask CA, et al: Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res 67: 6925-6935, 2007. (Pubitemid 47105540)
14. Liu LZ, Fang J, Zhou Q, Hu X, Shi X and Jiang BH: Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol 68: 635-643, 2005. (Pubitemid 41206017)
15. Fang J, Xia C, Cao Z, Zheng JZ, Reed E and Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19: 342-353, 2005. (Pubitemid 40316522)
16. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC and Pelling JC: Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog 47: 686-700, 2008.
17. Liu E, Hjelle B, Bishop JM: Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci USA 85: 1952-1956, 1988. (Pubitemid 24315802)
18. O'Bryan JP, Frye RA, Cogswell PC, et al: axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-5031, 1991. (Pubitemid 21895263)
19. Rochlitz C, Lohri A, Bacchi M, et al: Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13: 1352-1358, 1999. (Pubitemid 29429761)
20. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E and Andres AC: Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 12: 819-824, 2001. (Pubitemid 32655092)
21. Craven RJ, Xu LH, Weiner TM, et al: Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-797, 1995.
22. Ito T, Ito M, Naito S, et al: Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 9: 563-567, 1999. (Pubitemid 29296118)
23. Nemoto T, Ohashi K, Akashi T, Johnson JD and Hirokawa K: Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 65: 195-203, 1997. (Pubitemid 27472525)
24. Shieh YS, Lai CY, Kao YR, et al: Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-1064, 2005.
25. Hutterer M, Knyazev P, Abate A, et al: Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14: 130-138, 2008. (Pubitemid 351377987)
26. Sun WS, Fujimoto J and Tamaya T: Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann Oncol 14: 898-906, 2003. (Pubitemid 36827206)
27. Gustafsson A, Martuszewska D, Johansson M, et al: Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 15: 4742-4749, 2009.
28. Byers LA, Diao L, Wang J, et al: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19: 279-290, 2013.
29. Liu L, Greger J, Shi H, et al: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69: 6871-6878, 2009.
30. Holland SJ, Powell MJ, Franci C, et al: Multiple roles for the receptor tyrosine kinase axl in tumor formation. Cancer Res 65: 9294-9303, 2005. (Pubitemid 41507996)
31. Giles KM, Kalinowski FC, Candy PA, et al: Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 12: 2541-2558, 2013.
32. Birt DF, Walker B, Tibbels MG and Bresnick E: Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis 7: 959-963, 1986.
33. Liang YC, Huang YT, Tsai SH, Lin-Shiau SY, Chen CF and Lin JK: Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 20: 1945-1952, 1999.
34. Choi JS, Choi YJ, Park SH, Kang JS and Kang YH: Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: role of nuclear factor-kappa B. J Nutr 134: 1013-1019, 2004.
35. Plaumann B, Fritsche M, Rimpler H, Brandner G and Hess RD: Flavonoids activate wild-type p53. Oncogene 13: 1605-1614, 1996. (Pubitemid 26377491)
36. Lepley DM and Pelling JC: Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinog 19: 74-82, 1997. (Pubitemid 27296738)
37. Shukla S and Gupta S: Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 39: 114-126, 2004. (Pubitemid 38167115)
38. Li Y, Ye X, Tan C, et al: Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28: 3442-3455, 2009.
39. Ye X, Li Y, Stawicki S, et al: An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29: 5254-5264, 2010.
40. Gusenbauer S, Vlaicu P and Ullrich A: HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 32: 3846-3856, 2013.
41. Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860, 2012.
42. Postel-Vinay S and Ashworth A: AXL and acquired resistance to EGFR inhibitors. Nat Genet 44: 835-836, 2012.
43. Dufies M, Jacquel A, Belhacene N, et al: Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2: 874-885, 2011.
44. Mahadevan D, Cooke L, Riley C, et al: A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 26: 3909-3919, 2007. (Pubitemid 46884299)
45. Hong J and Belkhiri A: AXL mediates TRAIL resistance in esophageal adenocarcinoma. Neoplasia 15: 296-304, 2013.